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Objectives: There is ongoing debate regarding the optimal serum concentrations of 25-hydroxy-vitamin
D for musculoskeletal health, including osteoarthritis (OA). The aim of this prospective cohort study was
to determine whether serum 25-hydroxy-vitamin D concentrations were associated with the risk of hip
arthroplasty for OA.
Design: This study examined 9135 participants from the Australian Diabetes, Obesity and Lifestyle Study
who had serum 25-hydroxy-vitamin D measured in 1999e2000 and were aged 40 years at the
commencement of arthroplasty data collection. The incidence of hip arthroplasty for OA during 2002
e2011 was determined by linking cohort records to the Australian Orthopaedic Association National Joint
Replacement Registry.
Results: Over an average 9.1 (standard deviation (SD) 2.7) years of follow-up, 201 hip arthroplasties for
OA were identiﬁed (males n ¼ 90; females n ¼ 111). In males, a one-standard-deviation increase in 25-
hydroxy-vitamin D was associated with a 25% increased incidence (HR 1.25, 95% CI 1.02e1.56), with a
dose response relationship evident by quartiles of 25-hydroxy-vitamin D concentration (P for trend 0.04).
These results were independent of age, body mass index (BMI), ethnicity, smoking status, physical ac-
tivity, season of blood collection, latitude, hypertension and diabetes, area level disadvantage or after
excluding those with extreme low 25-hydroxy-vitamin D concentrations. No signiﬁcant association was
observed in women (HR 1.10, 95% CI 0.87, 1.39).
Conclusions: Increasing serum 25-hydroxy-vitamin D concentrations were associated with an increased
risk of hip arthroplasty for OA in males, while no signiﬁcant association was observed in females. The
mechanism for the association warrants further investigation.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved..M. Cicuttini, School of Public
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Osteoarthritis (OA) is the most common form of arthritis,
causing pain and functional disability. Symptomatic hip OA repre-
sents a substantial burden with one in four people developing this
condition in their lifetime1. The number of years lived with
disability for hip OA has increased over the last two decades2. Bone
is a dynamic tissue undergoing constant remodelling and plays antd. All rights reserved.
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biochemical studies have indicated that bone and cartilage pa-
thology are linked in OA3,4. Hip geometry is an important risk factor
for OA, with subtle bone microarchitectural changes predating
radiographic hip OA5,6.
There is ongoing debate regarding optimal serum concentra-
tions of 25-hydroxy-vitamin D [25(OH)D] for skeletal health7,8.
Vitamin D plays an essential role in promoting calcium absorption
to enable mineralization and promote healthy bones as well as
improve lower extremity muscle function and reduce falls risk9.
Vitamin D also has multiple biological functions in cartilage via
vitamin D receptors10. While articular cartilage loss is a key feature
of OA, OA is now recognised as a disease of the whole joint. The
interaction between bone and cartilage is believed to be central to
cartilage homoeostasis. Thus vitamin D status might affect the
development and progression of hip OA, either directly via its ef-
fects on cartilage, or indirectly via its effects on bone11. However,
the relationship between serum 25(OH)D concentrations and the
risk of hip OA is inconclusive11e14.While some studies reported that
low serum 25(OH)D concentrations were associated with an
increased prevalence and incidence of hip OA11,12, others showed
no association13,14. The relationship between serum 25(OH)D con-
centrations and health outcomes may be affected by several factors
such as season of blood collection, ageing, latitude, obesity, physical
activity, and smoking15. The previous studies on vitamin D and OA
had a number of limitations which make interpretation of the
ﬁndings difﬁcult, including small sample sizes11e13, cross-sectional
study design12, and failure to adjust for important confounders11,12.
As a result the role of serum 25(OH)D concentrations in the path-
ogenesis of OA remained unknown. Moreover, these studies have
used different methods to deﬁne hip OA, such as radiographic hip
OA11,12, clinical examination by physicians13 or the International
Classiﬁcation of Diseases codes14. One method for deﬁning OA is to
use arthroplasty, which identiﬁes severe hip OA relevant to
symptomatic disease burden and economic impact16,17. The aim of
this prospective cohort study was to determine whether serum
25(OH)D concentrations were associated with the risk of hip
arthroplasty for OA in a large cohort of Australian adults.Patients and methods
Study participants
The Australian Diabetes, Obesity and Lifestyle (AusDiab) Study is
a national, population-based cohort study of 11,247 people, aged
25 years, recruited by a stratiﬁed cluster sampling method,
involving seven strata (six states and the Northern Territory) and
clusters based on census collector districts, during 1999 to 200018.
The study was approved by the International Diabetes Institute
Ethics Committee and the Monash University Human Research
Ethics Committee18. All participants gave written informed con-
sent. For the current study, participants were restricted to those
aged 40 years at the commencement of arthroplasty data
collection (January 2002) by the Australian Orthopaedic Associa-
tion National Joint Replacement Registry (AOA NJRR), as arthro-
plasty for the treatment of OA is very uncommon under this age19.
Of the 11,247 AusDiab participants that attended a biomedical
evaluation and provided a fasting blood sample in 1999/2000, a
total of 2,112 were excluded as they were aged <40 years or had the
ﬁrst recorded arthroplasty as a revision surgery, leaving 9,135
participants eligible for the current study. The data linkage study
was approved by the Alfred Hospital Ethics Committee, the Uni-
versity of Adelaide and Monash University Human Research Ethics
Committees.Demographic, lifestyle factors, and socioeconomic position
assessments
Demographic and lifestyle data, including date of birth, gender,
ethnicity (Europid vs non-Europid), smoking (current-, ex- or
never), and leisure time physical activity (minutes per week), were
collected in 1999e2000 by trained interviewers using standardised
questionnaires as reported previously18. Physical activity was
assessed using the Active Australia Survey, which predominantly
assesses leisure-time physical activity which includes duration and
frequency of walking for recreation or transport; other moderate
activity e.g., lawn bowls, golf, and gentle swimming; and vigorous
activity e.g., gardening, tennis, jogging, cycling, and keep-ﬁt
exercise during the previous week20. Total physical activity repre-
sents the sum of the time spent walking (if continuous and 10 min
or more), the time spent doing other moderate intensity activities,
plus the time spent participating in vigorous intensity activity.
According to the current public health physical activity guidelines
recommendation, participants were categorized as insufﬁciently
active (reporting some moderate- or vigorous-intensity physical
activity but less than 150min in the last week), or sufﬁciently active
(reporting 150 min or more activity at a moderate- or vigorous-
intensity level in the last week)20. This physical activity measure
has been shown to provide acceptable precision [intra-class
correlation ¼ 0.59, 95% conﬁdence interval (CI) 0.52 to 0.65] and
validity (criterion validity ¼ 0.3) estimates of exercise among
adults20,21. Data on vitamin D supplement use was not obtained.
Area-level socioeconomic disadvantagewas estimated using the
Index of Relative Disadvantage code from the Socioeconomic In-
dexes for Areas (SEIFA). The index was developed by the Australian
Bureau of Statistics. This is a summary measure from a group of 20
variables (related to education, income, employment, family
composition, housing beneﬁts, car ownership, ethnicity, English
language proﬁciency, residential overcrowding) displaying di-
mensions of social disadvantage22. The index is constructed such
that high values reﬂect areas with high socioeconomic position
(relative advantage) and low values reﬂect areas with low socio-
economic position (relative disadvantage).
Anthropometric and clinical measurements
Height was measured to the nearest 0.5 cmwithout shoes using
a stadiometer. Weight was measured without shoes and in light
clothing to the nearest 0.1 kg using a mechanical beam balance.
Body mass index (BMI) was calculated as weight in kilogrammes
divided by height in metres squared18. Blood pressure was
measured with Dinamap/mercury sphygmomanometer18. Hyper-
tension was deﬁned as systolic and diastolic blood pressure >140/
90 mm Hg or current use of antihypertensive medication18.
Fasting plasma glucose (FPG) and 2-h plasma glucose (2-h PG)
were measured with an Olympus AU600 analyzer (Olympus Opti-
cal, Tokyo, Japan)18. Participants were classiﬁed as having known
diabetes mellitus if they reported having doctor diagnosed diabetes
mellitus and were either taking hypoglycaemic medication or had
an FPG 7.0 mmol/L or 2-h PG  11.1 mmol/L. Participants not
reporting having diabetes mellitus but who had an FPG7.0 mmol/
L or 2-h PG  11.1 mmol/L were classiﬁed as having newly diag-
nosed diabetes mellitus.
Assessment of vitamin D status and dietary calcium intake
Blood samples were stored at 70C until assayed. As previ-
ously reported23, serum 25(OH)D was measured in the entire
AusDiab population at baseline (1999/2000) using the Liaison
25(OH)D TOTAL (Liaison 25OHD) (DiaSorin Inc., Stillwater, MN), a
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assay coefﬁcient of variation of 7.0% at 45 nmol/L and 6.3% at
93 nmol/L. In 210 samples where fasting serum were not available,
ﬂuoride oxalate plasma (fasting plasma n ¼ 190; 2-h plasma post-
OGTT n ¼ 20) was used24. There was excellent agreement between
serum 25(OH)D concentrations collected from both tubes
(n ¼ 100): ﬂuoride oxalate plasma 25(OH)D ¼ 0.97  serum
25(OH)D þ 2.5,r2 ¼ 0.8924. Season of blood sampling was divided
into: Summer (Dec to Feb), Autumn (Mar to May), Winter (June to
Aug) and Spring (Sept to Nov)25. The latitude of each blood
collection centre was determined using the Google GPS tool (range
12e43S)24.
Total energy including dietary calcium intake was assessed us-
ing a self-administered validated food frequency questionnaire20,24.
Nutrient intake was calculated by multiplying the frequency of
consumption by standard portion weights, which were then con-
verted into nutrient intakes based on the NUTTAB95 nutrient
composition database20,24. Dietary calcium intake was adjusted for
total energy intake by using the residual method24.
Identiﬁcation of incident primary hip arthroplasty
Cases were identiﬁed from the AOA NJRR as those who under-
went a primary hip arthroplasty. Detailed information is available
on prostheses, patient demographics, type and reason for arthro-
plasty. Data are collected fromboth public and private hospitals and
validated using a sequential multi-level matching process against
State and Territory Health Department unit record data26.
Following the validation process and retrieval of unreported re-
cords, the Registry collects an almost complete set of data relating
to hip arthroplasty in Australia26. Matching of AusDiab participants
using ﬁrst name, surname, date of birth, and gender, to the AOA
NJRR in order to identify those who had an arthroplasty performed
between 1 January 2002 and 31 December 2011 was performed
using U.S. Bureau of the Census Record Linkage Software. This study
examined the ﬁrst hip arthroplasty with a contemporaneous
diagnosis of OA, as recorded in the AOA NJRR27. If one person had
multiple arthroplasties, such as bilateral hip arthroplasties, or both
knee and hip arthroplasties, the ﬁrst recorded procedure was
considered the event.
Statistical analysis
Independent (unpaired) samples t-tests (i.e., Student's t-test for
independent samples) for continuous variables or chi-squared tests
for categorical variables were used to compare the characteristics of
the participants with and without hip arthroplasty for OA. Cox
proportional hazard regression models were used to estimate the
hazard ratio (HR) with 95% CI for the incidence of hip arthroplasty
due to OA associated with serum 25(OH)D, with age as the time
scale. Follow-up for arthroplasty (calculation of person-time) began
at 1 January 2002, and ended at the date of ﬁrst hip arthroplasty for
OA or date of censoring. Participants were censored at either the
date of ﬁrst hip arthroplasty for indications other than OA, the date
of death, or end of follow-up (31 December 2011), whichever came
ﬁrst. To test whether associations of serum 25(OH)D with hip
arthroplasty risk were modiﬁed by sex, obesity, physical activity
(sufﬁcient vs insufﬁcient) or age (<65 years vs 65 years), in-
teractions were ﬁtted, and tested using the likelihood ratio test.
Since an interaction with sex was identiﬁed, all analyses were
performed for males and females separately, and adjusted for BMI,
smoking status, ethnicity, physical activity, season of blood collec-
tion and latitude (model 1). Area-level disadvantage, diabetic status
and hypertensionwere additionally adjusted for in model 2. Owing
to the importance of calcium in bone health, dietary calcium intakewas also adjusted in a separate model with other variables. As
walking and gardening are outdoor activities which might affect
serum 25(OH)D concentrations, additional modelling was done
including walking and gardening time instead of physical activity.
Serum 25(OH)D was standardized so that the HRs represent the
effect of a one-standard-deviation (SD) difference in 25(OH)D.
Serum 25(OH)D was also categorized into gender speciﬁc quartiles.
The lowest quartile was used as the referent category. Linear as-
sociation between 25(OH)D and hip arthroplasty risk was exam-
ined using the likelihood ratio test. The P-value for trend was
calculated by assigning the participants the median value of each
serum 25(OH)D category and including this as a continuous vari-
able in the model. To ensure that the result was not driven by
extremely low 25(OH)D concentrations, additional analysis was
done excluding those with vitamin D deﬁciency (25(OH)
D < 25 nmol/L, n ¼ 276). Death is an event that precludes the
assessment of hip arthroplasty for hip OA, i.e., a competing event.
To counter this issue we performed competing-risks regression
according to the method of Fine and Gray. Tests based on Cox
regression methods and Competing-risks regression showed no
evidence that underlying assumptions were violated for any anal-
ysis. All statistical analyses were performed using Stata 12.0 (Sta-
taCorp LP., College Station, TX, USA).
Results
Over 9.1 (SD 2.7) years of follow-up, 201 hip arthroplasties for
OA were identiﬁed (men n ¼ 90; women n ¼ 111). The character-
istics of the participants are presented in Table I. Both males and
females who received a hip arthroplasty for OA were older, having
greater BMI, and more likely to be Europid and hypertensive.
Since sex modiﬁed the associations between serum 25(OH)D
concentration and hip arthroplasty risk (P¼ 0.05), men andwomen
were examined separately (Table II). In men, a one SD increase in
25(OH)D was associated with a 25% increased risk of hip arthro-
plasty for OA (HR 1.25, 95% CI 1.02, 1.56). When the 25(OH)D con-
centration was examined as quartiles, there was a dose response
relationship between increasing quartiles of serum 25(OH)D con-
centration and the risk of hip arthroplasty forOA (P for trend¼0.04),
independent of age, BMI, ethnicity smoking status, physical activity,
season of blood collection and latitude, hypertension and diabetes,
and socioeconomic position. Adjustment for walking and gardening
time instead of physical activity did not change the association (HR
1.25, 95% CI 1.01, 1.54). Additional adjustment for dietary calcium
intake did not change the association (data not shown). In contrast,
there was no associations between serum 25(OH)D concentration
and hip arthroplasty for OA in women (HR 1.10, 95% CI 0.87, 1.39).
When we excluded participants with serum 25(OH)D concentra-
tions<25 nmol/L, a one SD increase in 25(OH)Dwas associatedwith
a23% increased incidence of hip arthroplasty inmen (HR1.23, 95%CI
1.01, 1.53). The subdistribution hazard ratios derived from
competing-risks regression analysis were very similar as the HRs
from the Cox regression analysis (data not shown).
Discussion
In this prospective cohort study, higher serum 25(OH)D con-
centrations predicted an increased risk of hip arthroplasty for OA in
males but not in females, independent of age, BMI, smoking status,
physical activity, season of blood collection and latitude, comor-
bidities and socioeconomic position. These results persisted when
those with low concentrations of 25(OH)D were excluded.
The data is conﬂicting regarding the association between
serum 25(OH)D concentrations and the risk of hip OA11e14. Our
ﬁndings suggest that serum 25(OH)D concentrations are
Table I
Baseline characteristics of participants with and without hip OA over the follow-up
period
Hip OA No hip OA P Value
Male
Number 90 4052
Age, years 60.2 (10.2) 56.0 (12.0) <0.001
Europids, n (%) 88 (97.8) 3,647 (90.1) 0.02
Area-level disadvantage (lowest tertile %) 34 (38.6) 1,276 (32.0) 0.33
BMI, kg/m2 28.6 (3.5) 27.3 (4.1) 0.003
Current/ex-smoker, n (%) 9 (11.0) 633 (16.0) 0.18
Physical activity, min/week 250 (263) 316 (304) 0.09
Walking, times/week 3.4 (0.4) 4.0 (0.1) 0.27
Gardening, times/week 1.1 (0.2) 0.8 (0.0) 0.27
Blood collection time, n (%) 0.004
Summer (DeceFeb) 4 (4.4) 457 (11.3)
Autumn (MareMay) 35 (38.9) 954 (23.5)
Winter (JuneeAug) 26 (28.9) 1,354 (33.4)
Spring (SepteNov) 25 (27.8) 1,287 (31.8)
Latitude by region, n (%) 0.006
<30 12 (13.3) 1,058 (26.1)
30e35 39 (43.3) 1,755 (43.3)
>35 39 (43.3) 1,239 (30.6)
Diabetes, n (%) 7 (7.8) 477 (11.9) 0.24
Hypertension, n (%) 49 (54.5) 1,703 (42.3) 0.02
Dietary calcium, mg/day 904 (364) 919 (340) 0.35
Serum 25(OH)D, nmol/L 71.6 (21.9) 68.6 (24.8) 0.24
Female
Number 111 4853
Age, years 62.2 (10.7) 55.6 (12.2) <0.001
Europids, n (%) 107 (96.4) 4,360 (89.9) 0.02
University/Further education, n (%) 33 (29.7) 1,470 (30.3) 0.90
Area-level disadvantage (lowest tertile %) 32 (29.1) 1,595 (33.4) 0.64
BMI, kg/m2 28.0 (5.2) 27.0 (5.5) 0.07
Current/ex-smoker, n (%) 16 (14.7) 596 (12.5) 0.50
Physical activity, min/week 218 (265) 223 (282) 0.83
Walking, times/week 2.9 (0.3) 3.4 (0.1) 0.24
Gardening, times/week 0.6 (0.1) 0.5 (0.0) 0.33
Blood collection time, n (%) 0.14
Summer (DeceFeb) 14 (12.6) 560 (11.5)
Autumn (MareMay) 35 (31.5) 1,101 (22.7)
Winter (JuneeAug) 32 (28.8) 1,589 (32.7)
Spring (SepteNov) 30 (27.0) 1,603 (33.0)
Latitude by region, n (%) 0.29
<30 30 (27.0) 1,286 (26.5)
30e35 42 (37.8) 2,156 (44.4)
>35 39 (35.1) 1,411 (29.1)
Diabetes, n (%) 9 (8.2) 403 (8.4) 0.93
Hypertension, n (%) 54 (48.6) 1,688 (35.0) 0.003
Dietary calcium, mg/day 881 (297) 881 (340) 0.51
Serum 25(OH)D, nmol/L 57.2 (20.6) 57.3 (22.1) 0.96
Data are presented as mean ± SD, or as percentage.
Table II
Relationship of serum 25(OH)D concentrations with incidence of hip arthroplasty for OA
Model 1 hazard ratio (95% CI)
Male
Serum 25(OH)D (per SD) 1.25 (1.02, 1.56)
Serum 25(OH)D Quartile
1 (51 nmol/L) 1.00
2 (52e65 nmol/L) 2.03 (1.01, 4.03)
3 (66e81 nmol/L) 2.18 (1.07, 4.05)
4 (82 nmol/L) 2.30 (1.09, 4.82)
P for trend 0.02
Female
Serum 25(OH)D (per SD) 1.10 (0.87, 1.39)
Serum 25(OH)D Quartile
1 (41 nmol/L) 1.00
2 (42e54 nmol/L) 1.30 (0.76, 2.23)
3 (55e69 mmol/L) 1.10 (0.62, 1.95)
4 (70 nmol/L) 1.29 (0.71, 2.33)
P for trend 0.54
Model 1 adjusted for BMI, ethnicity, smoking status, physical activity, season of blood co
Model 2 adjusted for model 1 and hypertension, diabetes, and Area-level disadvantage.
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but not women. The Mini-Finland Health Examination Survey, a
22 year follow-up study of 805 Finnish people including 22 with
hip OA13, and the Health 2000 Survey of Finland, a 10 years
follow-up study of 5,274 Finnish people including 45 with hip
OA14, concluded that low concentrations of 25(OH)D do not
contribute to the development of hip OA. However, the Health
2000 Survey of Finland found a weak trend (P for trend 0.053)
for increasing concentration of serum 25(OH)D to be associated
with increased risk of hip OA14. It is difﬁcult to compare ﬁndings
across studies because the baseline serum 25(OH)D concentra-
tions in the two Finnish studies were 12e25 nmol/L lower than
in our study, and the two Finnish studies had smaller numbers of
outcome. Similarly, a recent systematic review found limited or
conﬂicting evidence for an association between concentrations
of serum 25(OH)D and the incidence or progression of radio-
graphic hip OA28. In contrast, increasing serum concentrations of
25(OH)D were associated with decreased incidence of radio-
graphic hip OA over an average period of 8 years in 237 women
from the Study of Osteoporotic Fractures11. Similarly, the Oste-
oporotic Fractures in Men Study, which was a cross-sectional
study from six areas of the US, found that men with vitamin D
deﬁciency (37.44 nmol/L) were more likely to have radio-
graphic hip OA12. However, the participants of these two studies
were older (>70 years at baseline) than our population, and the
Study of Osteoporotic Fractures did not adjust for season of
blood collection11, which is strongly associated with serum
25(OH)D concentrations.
The ﬁnding of an increased risk of hip arthroplasty for OA inmen
with increasing serum 25(OH)D concentrations, after adjusting for
potential confounding, is difﬁcult to explain. We found that men in
the highest quartile of serum 25(OH)D concentration were of
similar age and socioeconomic position, more physically active, had
lower BMI and were less likely to be diabetic and hypertensive than
those in the lower quartiles, suggesting they were healthier and
more ﬁt for undergoing hip arthroplasty (Supplementary Table 1).
Nevertheless, the rate of hip arthroplasty was similar across all the
tertiles of the socioeconomic status (2.1% highest, 2.3% middle and
2.3% lowest tertile, P ¼ 0.90) and in the diabetic and non-diabetic
men (1.5% vs 2.2%, P ¼ 0.24), but it was higher in obese men
(non-obese vs obese, 1.9% vs 3.2%, P ¼ 0.02) and those who were
hypertensive (non-hypertensive vs hypertensive, 1.7% vs 2.8%,
P ¼ 0.02).P Model 2 hazard ratio (95% CI) P
0.02 1.26 (1.01, 1.56) 0.04
1.00
0.04 2.02 (1.01, 4.06) 0.05
0.03 2.17 (1.08, 4.06) 0.03
0.03 2.30 (1.09, 4.82) 0.03
0.04
0.44 1.11 (0.88, 1.41) 0.39
1.00
0.35 1.21 (0.70, 2.09) 0.50
0.75 1.08 (0.61, 1.91) 0.80
0.40 1.29 (0.71, 2.34) 0.40
0.49
llection and latitude.
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25(OH)D concentrations and risk of end-stage hip OA requiring hip
arthroplasty is unclear. Vitamin D is important in regulating cal-
cium homoeostasis by enabling calcium absorption though the
small intestine29 and the vitamin D receptor present in the bone
forming osteoblast cells directly affects osteoblast growth and dif-
ferentiation by stimulating bone formation30. Each of these protects
against predominantly anabolic state of bone which may result in
bone sclerosis or altered hip bone geometry that have a central role
in hip OA31,32.
Another possible mechanism for the positive association be-
tween serum 25(OH)D and end-stage hip OA may be mediated
through increased bone mineral density (BMD). Serum 25(OH)D
(with or without calcium) and BMD are signiﬁcantly related to one
another33,34. A recent study showed that increased BMD was
associated with cam-type femoroacetabular impingement charac-
terised by a convex deformity of the antero-superior femoral
headeneck junction35. Cam-type deformity is associated with
development of painful degenerative hip disease through chondral
injury and eventual cleavage of the cartilage layer5,35,36. Both the
Chingford study and the Framingham study reported an increase of
up to 15% in BMD in patients with OA compared with those
without37,38.
In our study those in the highest quartile of serum 25(OH)D
concentration were more active. Thus, the positive association be-
tween concentration of serum 25(OH)D and the risk of hip OA may
be mediated through physical activity. Physical activity might
accelerate “wear and tear” of the hip joints, resulting in joint injury
which ultimately will lead to hip OA. Occupational or recreational
physical activity has been associated with increased incidence of
physician-diagnosed hip OA39, and prolonged regular sporting ac-
tivity has been associatedwith increased risk of hip arthroplasty for
OA40. We have adjusted for time spent in leisure-time physical
activity, or walking and gardening time, indicating our results could
not be explained by recreational activity. Our study participants
were drawn from the community, thus less likely to be involved in
regular sporting activity. However, we do not have detailed occu-
pational activity data which is an important risk factor for hip OA41,
so we were not able to address whether the association we
observed was confounded by occupational activity.
The reason for the ﬁnding that there was detrimental effect of
increasing serum 25(OH)D on the incidence of hip OA in males, but
not in females, is not clear. However, we found that the concen-
trations of serum 25(OH)D were signiﬁcantly different between
males and females (mean 68.6 ± 24.8 nmol/L vs 57.3 ± 22.1 nmol/L,
P 0.001). It is possible that this gender difference in serum 25(OH)
D may inﬂuence other biochemical or hormonal measures related
to bone and/or cartilage health. For instance, sex steroids have been
found to be associated with bone geometric structure change in the
hip42. Besides, there are mutual interaction between vitamin D and
estrogenic compounds43, which might also explain our ﬁnding.
The strengths of our study include its prospective design, large
sample size, measurement of serum 25(OH)D concentrations in the
entire population at baseline, adjustment of season and latitude,
and the validation and completeness of AOA NJRR data26,27. How-
ever, there are a number of limitations. The AusDiab participants
were not investigated at baseline for hip OA. It is likely that some
participants already had hip OA at baseline. Thus in this study
serum 25(OH)D may be a marker of OA incidence, progression, or a
marker of being selected for arthroplasty. Serum 25(OH)D was only
measured at baseline, which may not reﬂect long term vitamin D
status.We deﬁned OA based on arthroplasty. However, arthroplasty
as the treatment of OA may be inﬂuenced by a number of factors
such as access to health care, socioeconomic status, and patient
preference44, in addition to disease severity. This study was carriedout in Australia where there is universal health cover, so access to
arthroplasty is available to all. Nevertheless, males with higher
serum 25(OH)D concentrations may be more bound to maintain
their moving ability and thus have an earlier arthroplasty.
Furthermore, we performed the analysis on an age scale and
adjusted for BMI, ethnicity, smoking status, physical activity, co-
morbidity and socioeconomic positioning to counter this issue. We
have also compared the rate of hip replacement in different so-
cioeconomic position categories and found no difference (2.1%
highest, 2.3% middle and 2.3% lowest tertile, P ¼ 0.90). We did not
have joint replacement data prior to 2002. This may have resulted
in non-differential misclassiﬁcation of hip replacement, which is
likely to bias the results to the null. It is possible that there is re-
sidual confounding that can contribute to the concentration of
serum 25(OH)D, for example vitamin D supplementation and
occupational and sports activities that might have provided alter-
native explanations of our ﬁndings. The results must be taken in
context of the whole body of evidence. The ﬁndings of this study
add to the ongoing debate regarding the optimal serum concen-
trations of 25(OH)D for joint health after controlling for potential
confounders. Nevertheless, our population was community based
and so it is unlikely that many of them were engaged in regular
sporting activity. Finally, examination of hip arthroplasty for OA
was not the primary goal of the AusDiab study.
Owing to a number of limitations, previous observational
studies have reported inconclusive ﬁndings regarding the associa-
tion between serum 25(OH)D concentrations and the risk of hip
OA11e14. The hypothesis that vitamin D has beneﬁcial effect on
skeletal health and the results from some observational studies
showing vitamin D insufﬁciency to be associated with a wide va-
riety of disorders such as fractures, cardiovascular disease, and
cancer have resulted in the use of widespread vitamin D supple-
mentation45. Recent ﬁndings from sequential meta-analysis sug-
gest that vitamin D supplementation with or without calcium does
not reduce adverse skeletal outcomes in community-dwelling in-
dividuals46. Our study adds to the ongoing debate regarding the
optimal serum concentrations of vitamin D for skeletal health
particularly in the setting of widespread vitamin D
supplementation.
This study showed that increasing serum 25(OH)D concentra-
tions were associated with an increased risk of hip arthroplasty for
OA in males, while no signiﬁcant association was observed in fe-
males. The mechanism underlying the association warrants further
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